Summary Judgment Denial Clears Path For Abilify Trials
Law360 (March 16, 2018, 10:11 PM EDT) -- A Florida federal judge late Thursday released a redacted version of an order denying a bid for summary judgment from Otsuka Pharmaceutical and Bristol-Meyers Squibb in multidistrict litigation over alleged side effects of the anti-psychotic drug Abilify, paving the way for trials in consumers' cases this summer.
U.S. District Judge M. Casey Rodgers based her decision, which she originally issued the under seal to the parties on Jan. 22, on her determination that the consumers have shown their general causation evidence is sound and reliable and that there is a genuine dispute of material fact over whether Abilify can cause compulsive...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!